ZENITH — Zilebesiran in Uncontrolled Hypertension
Hypertension with Cardiovascular Risk
Indication: Hypertension
Sponsor: Alnylam Pharmaceuticals · ALN-AGT01-008 · NCT07181109
About this study
Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.
To evaluate whether zilebesiran, a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen, improves blood pressure control and cardiovascular outcomes in adults with uncontrolled hypertension and elevated cardiovascular risk.
Study details
- Sponsor
- Alnylam Pharmaceuticals
- Protocol
- ALN-AGT01-008
- Phase
- Phase 3
- Indication
- Hypertension with Cardiovascular Risk
- Status
- Active — enrolling
- Principal Investigator
- Dr. William W. O'Neill, MD, FACC
High-level eligibility
- Adults 18+ with uncontrolled hypertension
- Established cardiovascular disease or high cardiovascular risk
- On stable antihypertensive therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
For patients
Read: Hypertension Clinical Trials — A Patient's Guide →
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.